Updates from Syncona and our portfolio companies
London, 5 July, 2019 – Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, will present preclinical data on its gene therapy development candidate for Gaucher Disease at the European Working group on Gaucher Disease (EWGGD) in Auvergne, France, July 4-6 2019. The Freeline program FLT200 is a liver-directed Adeno-associated virus (AAV) gene therapy for the treatment of type 1 Gaucher Disease and is designed to increase levels of beta-glucocerebrosidase (GCase) in macrophages of Gaucher’s Disease patients.
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that Anne Prener has completed her strategic objective of bringing Freeline into the clinic with two programs and is stepping down as Chief Executive Officer. Under Anne’s leadership, the Company has made excellent progress, enrolling several cohorts of patients in a Phase 1/2 study for Haemophilia B and preparing to enroll patients in its Fabry program in the coming weeks.
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, presented pre-clinical data of FLT190, a novel proprietary AAV gene therapy to treat Fabry Disease at the 6th Update on Fabry Disease in Prague, Czech Republic.
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, has secured a collaborative grant of £1.3 million from Innovate UK to lead a supply chain model and delivery development project in partnership with Symbiosis Pharmaceutical Services (Symbiosis) and the Cell and Gene Therapy Catapult (CGTC). The project is intended to create a UK based novel viral vector supply chain and to increase the speed of the Freeline production cycle by over 25%.
Freeline announced today it has signed a multi-year agreement with Brammer Bio (Brammer), a leading gene therapy contract development and manufacturing organisation, to secure a dedicated AAV manufacturing suite in Brammer’s state-of-the-art Cambridge, MA facility. This agreement will allow Freeline to meet the commercial demand of the FLT180a program for Haemophilia B. Freeline has now deployed its iCELLis®-based mammalian cell manufacturing at three separate locations, including Brammer, the Cell and Gene Therapy Catapult outside of London, UK, and at a European CMO.
Freeline, a biotech company focused on developing curative gene therapies for chronic systemic diseases, together with Pall Corporation (Pall), a leading manufacturer of advanced biopharmaceutical processing technology, are pleased to announce the completion of the first full-scale run in Freeline’s newly commissioned Good Manufacturing Practice (GMP) facility located at the Cell and Gene Therapy Catapult (Catapult) facility in Stevenage, UK.
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced that it will deliver two oral and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting being held from 29th April to 2nd May, 2019 in Washington D.C.
Freeline, a biotechnology company focused on developing curative gene therapy for chronic systemic diseases, today announces a new program for Gaucher Disease, an inherited metabolic disorder characterized by the progressive build-up of glucocerebroside in lysosomes throughout the body. Freeline is targeting Type 1 Gaucher Disease, the most common and non-neuronopathic form of the disease.
Freeline is pleased to announce the appointment of Brian M. Silver as Chief Financial Officer and Head of Corporate Development. Brian will be based in New York, as the Company establishes offices in the United States.
Freeline will develop a ‘next-generation’ therapy platform at the Cell and Gene Therapy Catapult’s UK-based large-scale GMP manufacturing centre. Company will further develop proprietary viral vector manufacturing technology for bleeding and other disorders.